Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
Cancer Prev Res (Phila). 2010 Jun;3(6):681-5. doi: 10.1158/1940-6207.CAPR-10-0101.
An important report in this issue of the journal by Vogel et al. (beginning on p. 696) discloses long-term follow-up data of the Study of Tamoxifen and Raloxifene (STAR) showing persisting strong effects of both drugs in preventing invasive and noninvasive breast cancer after drugs were stopped in 2006. In addition, safety improved with longer follow-up (median of 81 months versus 47 months for the initial report). For 12 years, the public has avoided Food and Drug Administration-approved tamoxifen or raloxifene for breast cancer risk reduction; it is time to reemphasize the great preventive benefit of these agents to the public.
本期杂志中，Vogel 等人的一篇重要报告（第 696 页开始）披露了他莫昔芬和雷洛昔芬研究（STAR）的长期随访数据，表明在 2006 年停药后，两种药物在预防浸润性和非浸润性乳腺癌方面仍具有持续的强大作用。此外，随着随访时间的延长，安全性也得到了改善（中位数分别为 81 个月和初始报告的 47 个月）。12 年来，公众一直在避免使用经食品和药物管理局批准的他莫昔芬或雷洛昔芬来降低乳腺癌风险；现在是向公众重新强调这些药物的巨大预防益处的时候了。
